Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
BIAF
bioAffinity Technologies, Inc.
CAPPED RATING
bioAffinity Technologies, Inc. (BIAF) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
2.0
/ 5.0
C-
Value
B-
Factor Score
3.0
/ 5.0
Growth
D
Factor Score
1.2
/ 5.0
Profitability
C+
Factor Score
2.8
/ 5.0
Momentum
F
Factor Score
0.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-3.3
EV / EBITDA
-0.2
Rev Growth YoY
-26.0%
Gross Margin
27.0%
Price Return 3M
-71.8%
Price Return 12M
-92.9%
Catalyst Signal
0.00
Market Cap
$3.6M
TTM Revenue
$5.5M
Price / Sales
0.7
ROE
-240.5%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.0) | D (1.2) | C+ (2.8) | F (0.5) | C+ (2.6) | C- (2.0) |
| 2026-11-10 | B- (3.0) | C+ (2.6) | C+ (2.6) | F (0.5) | C+ (2.6) | C (2.3) |
| 2026-11-03 | B- (3.0) | C+ (2.6) | C+ (2.7) | F (0.6) | C+ (2.7) | C (2.3) |
| 2026-10-27 | B- (3.0) | C+ (2.6) | C+ (2.7) | F (0.5) | C+ (2.6) | C (2.3) |
| 2026-10-20 | B- (3.0) | C+ (2.6) | C+ (2.7) | F (0.5) | C+ (2.6) | C (2.3) |
Page
1
of
4